Literature DB >> 12906931

Antidiabetic and antimalarial biguanide drugs are metal-interactive antiproteolytic agents.

Deacon Sweeney1, Michael L Raymer, Thomas D Lockwood.   

Abstract

Various biguanide derivatives are used as antihyperglycemic and antimalarial drugs (e.g., 1,1-dimethyl biguanide (metformin), phenylethyl biguanide (phenformin), N-(4-chlorophenyl)-N'-(isopropyl)-imidodicarbonimidic diamide (proguanil)); however, no common mechanism has been suggested in these controversial therapeutic actions. Biguanides bind endogenous metals that inhibit cysteine proteases independently, e.g., Zn(2+), Cu(2+), Fe(3+). Here, various biguanide derivatives are reported to be metal-interactive inhibitors of cathepsin B from mammals and falcipain-2 from Plasmodium falciparum. Structural homologies were identified among the Phe-Arg protease substrate motif and the metal complexes of phenformin and proguanil. Molecular modeling revealed that the position of the scissile amide substrate bond corresponds to the biguanide-complexed inhibitory metal when the phenyl groups are homologously aligned. Binding of the phenformin-metal complex within the active site of human cathepsin B was modeled with computational docking. A major binding mode involved binding of the drug phenyl group at the protease S2 subsite, and the complexed inhibitory metal shared between the drug and the protease Cys29-His199 catalytic pair. Cysteine protease inhibition was assayed with carbobenzyloxy-PHE-ARG-7-aminomethylcoumarin substrate. In the absence of metal ions, phenformin was a weakly competitive protease inhibitor (apparent K(i) several microM); however, metformin was noninhibitory. In contrast, the metal complexes of both metformin and phenformin were protease inhibitors with potency at therapeutic concentrations. Biguanide-metal complexes were more potent cysteine protease inhibitors than either the biguanide or metal ions alone, i.e., synergistic. Similar to chloroquine, therapeutic extracellular concentrations of metformin, phenformin, and proguanil caused metal-interactive inhibition of lysosomal protein degradation as bioassayed in primary tissue using perfused myocardium. The biguanide moiety is identified as a past and future structural scaffold for synthesis of many protease inhibitors. Results are discussed in relation to Zn(2+)-interactive inhibition of insulin degradation in hormone target tissues, and Fe(3+)-interactive inhibition of hemoglobin degradation in parasite food vacuoles. Previous studies on insulin hypercatabolism and insulin resistance are speculatively reviewed in light of present findings.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12906931     DOI: 10.1016/s0006-2952(03)00338-1

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  12 in total

1.  Responsiveness of parasite Cys His proteases to iron redox.

Authors:  Thomas D Lockwood
Journal:  Parasitol Res       Date:  2006-07-06       Impact factor: 2.289

Review 2.  Protection by metformin against severe Covid-19: An in-depth mechanistic analysis.

Authors:  Nicolas Wiernsperger; Abdallah Al-Salameh; Bertrand Cariou; Jean-Daniel Lalau
Journal:  Diabetes Metab       Date:  2022-05-31       Impact factor: 8.254

Review 3.  Therapeutic Concentrations of Metformin: A Systematic Review.

Authors:  Farshad Kajbaf; Marc E De Broe; Jean-Daniel Lalau
Journal:  Clin Pharmacokinet       Date:  2016-04       Impact factor: 6.447

4.  Insulin versus oral agents in the management of Cystic Fibrosis Related Diabetes: a case based study.

Authors:  Gary M Onady; Leora J Langdon
Journal:  BMC Endocr Disord       Date:  2006-06-21       Impact factor: 2.763

Review 5.  Biguanide is a modifiable pharmacophore for recruitment of endogenous Zn2+ to inhibit cysteinyl cathepsins: review and implications.

Authors:  Thomas D Lockwood
Journal:  Biometals       Date:  2019-05-01       Impact factor: 2.949

Review 6.  Pathogenesis and Management of COVID-19.

Authors:  Khalid O Alfarouk; Sari T S AlHoufie; Samrein B M Ahmed; Mona Shabana; Ahmed Ahmed; Saad S Alqahtani; Ali S Alqahtani; Ali M Alqahtani; AbdelRahman M Ramadan; Mohamed E Ahmed; Heyam S Ali; Adil Bashir; Jesus Devesa; Rosa A Cardone; Muntaser E Ibrahim; Laurent Schwartz; Stephan J Reshkin
Journal:  J Xenobiot       Date:  2021-05-21

Review 7.  A marriage of two "Methusalem" drugs for the treatment of psoriasis?: Arguments for a pilot trial with metformin as add-on for methotrexate.

Authors:  Hartmut Glossmann; Norbert Reider
Journal:  Dermatoendocrinol       Date:  2013-04-01

8.  Destabilization of MYC/MYCN by the mitochondrial inhibitors, metaiodobenzylguanidine, metformin and phenformin.

Authors:  Stephanie S Wang; Ruth Hsiao; Mariko M Limpar; Sarah Lomahan; Tuan-Anh Tran; Nolan J Maloney; Naohiko Ikegaki; Xao X Tang
Journal:  Int J Mol Med       Date:  2013-11-01       Impact factor: 4.101

9.  Metformin directly targets the H3K27me3 demethylase KDM6A/UTX.

Authors:  Elisabet Cuyàs; Sara Verdura; Laura Llorach-Pares; Salvador Fernández-Arroyo; Fedra Luciano-Mateo; Noemí Cabré; Jan Stursa; Lukas Werner; Begoña Martin-Castillo; Benoit Viollet; Jiri Neuzil; Jorge Joven; Alfons Nonell-Canals; Melchor Sanchez-Martinez; Javier A Menendez
Journal:  Aging Cell       Date:  2018-05-08       Impact factor: 9.304

Review 10.  The Metformin Mechanism on Gluconeogenesis and AMPK Activation: The Metabolite Perspective.

Authors:  Loranne Agius; Brian E Ford; Shruti S Chachra
Journal:  Int J Mol Sci       Date:  2020-05-03       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.